Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the persistently muggy temperatures enveloping the Pharmalot campus. After all, the birds are still chirping and the skies are crystal clear. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Our choice today is golden French toast. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …
Endo International, which is facing thousands of lawsuits alleging it fueled the opioid addiction crisis, said it is likely to file for bankruptcy imminently, The Wall Street Journal writes. The company is in negotiations with a group of senior lenders that it expects will result in an agreement for a chapter 11 filing. Endo is also in talks with opioid litigants as well as other creditors but did not say that it has reached a proposed deal with them. Endo has planned to proceed toward filing for bankruptcy without a comprehensive agreement in place with the various states, municipalities, and private plaintiffs suing the company for its role in producing and distributing opioids.
The U.S. will allow the use of fractional doses of monkeypox vaccine, a plan that could result in five times as many people being vaccinated than the current approach, STAT tells us. The decision comes days after U.S. Health and Human Services Secretary Xavier Becerra declared the monkeypox outbreak a public health emergency. On Tuesday, Becerra issued a so-called 564 determination, which gives the U.S. Food and Drug Administration the power to issue emergency use authorizations for vaccines. In this case, it gives the FDA authority to permit changes to the way the Jynneos monkeypox vaccine, made by Bavarian Nordic, is administered.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect